635311-42-1

Basic information

• Product Name: benzyl 3-oxocyclopentylcarbamate
• Synonyms: benzyl 3-oxocyclopentylcarbamate;benzyl N-(3-oxocyclopentyl)carbamate;β-benzyloxycarbonylamino-cyclopentanone
• CAS NO: 635311-42-1
• Molecular Formula: C₁₃H₁₅NO₃
• Molecular Weight: 233.2631
• Mol File: 635311-42-1.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 415.0±44.0 °C(Predicted)
• Appearance: /
• Density: 1.19±0.1 g/cm3(Predicted)
• PKA: 11.69±0.20(Predicted)
• CAS DataBase Reference: benzyl 3-oxocyclopentylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: benzyl 3-oxocyclopentylcarbamate(635311-42-1)
• EPA Substance Registry System: benzyl 3-oxocyclopentylcarbamate(635311-42-1)

Safety Data

• Hazardous Substances Data: 635311-42-1(Hazardous Substances Data)

Upstream product

• 98-78-2 3-Oxo-cyclopentanecarboxylic acid 
• 100-51-6 benzyl alcohol 
• 501-53-1 benzyl chloroformate 
• 930-30-3 cyclopent-2-enone 
• 621-84-1 O-benzyl carbamate 
• 939426-84-3 [cis-(+/-)]-(3-hydroxycyclopentyl)carbamic acid phenylmethyl ester 
• 1003-03-8 Cyclopentamine 

Downstream Products

• 939525-61-8 3,3-difluorocyclopentanamine 
• 939398-48-8 3,3-difluorocyclopentan-1-amine hydrochloride 
• 1119103-53-5 benzyl 6,7-dihydro-3-nitro-5H-cyclopenta[b]pyridin-6-ylcarbamate 
• 1119103-59-1 benzyl 6,7-dihydro-3-nitro-5H-cyclopenta[b]pyridin-5-ylcarbamate 
• 939385-02-1 benzyl 3,3-difluorocyclopentylcarbamate 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS

Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.